Results 71 to 80 of about 2,068 (215)

Opportunities to improve the adoption of health-related quality of life evidence as part of the French Health Technology Assessment process

Health Research Policy and Systems, 2023
Objectives Patient’s health-related quality of life (HRQoL) is an important outcome measure that is considered by many payers and health technology assessment (HTA) bodies in the evaluation of treatments.
Hugo Larose, Myrto Lee, Jens Grueger, Amélie Anota, Nicolas Naïditch, Bruno Falissard, Mario Di Palma, Olivier Chassany, Laura Khalfallah-Neelz, Sarah Palazuelos-Muñoz, Aymeric Tetafort   +10 more
doaj   +1 more source

Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review

European Journal of Haematology, Volume 115, Issue 2, Page 104-116, August 2025.
ABSTRACT Objectives The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior ...
Bastian von Tresckow, Pau Abrisqueta, Irene Zamanillo, Ángel Serna, Yuting Kuang, Jennifer Uyei, Mohsin Shah, Laura Walsh, Eileen Thorley, Krystal Cantos, Emaan Rashidi, Christian Hampp, Jessica J. Jalbert, Alexi N. Archambault, Yingxin Xu, Shivani Aggarwal, Srikanth Ambati, Hesham Mohamed, Qiufei Ma, Ana Jiménez‐Ubieto   +19 more
wiley   +1 more source

Further Practical Guidance on Adjusting Time‐To‐Event Outcomes for Treatment Switching

Pharmaceutical Statistics, Volume 24, Issue 4, July/August 2025.
ABSTRACT The objective of this article is to bring together the key current information on practical considerations when conducting statistical analyses adjusting long‐term outcomes for treatment switching, combining it with learnings from our own experience, thus providing a useful reference tool for analysts.
Claire Watkins, Eva Kleine, Miguel Miranda, Emmanuel Bourmaud, Orlando Doehring   +4 more
wiley   +1 more source

OP94 Is The National Institute for Health And Care Excellence In The United Kingdom More Innovation-Friendly Than The German Institute For Quality And Efficiency in Health Care In Germany? [PDF]

, 2017
INTRODUCTION:Whereas Health Technology Assessments (HTAs) by the National Institute for Health and Care Excellence (NICE) rely heavily on cost utility analysis, HTAs by the German Institute for Quality and Efficiency in Health Care (IQWiG) and the ...
Michael Schlander, Ramon Schaefer
core   +1 more source

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

BMC Health Services Research, 2020
Background Value-based pricing (VBP) of new drugs has been suggested both as a way to control health expenditures and to maximize health benefits based on the available resources. The purpose of this work is to present a simple mathematical proof showing
Afschin Gandjour
doaj   +1 more source

Enhancing Drug Development for Paediatric Pulmonary Hypertension—An Integrative Perspective

Pulmonary Circulation, Volume 15, Issue 3, July 2025.
ABSTRACT As with adult pulmonary hypertension (PH), high morbidity and mortality persist with diverse types of paediatric PH. Despite major advances in pharmacologic therapies based on extensive studies in adult PH, few drugs have been comprehensively studied in neonates, infants, and children, leaving current paediatric PH care largely dependent on ...
Steven H. Abman, Sylvia M. Nikkho, Rolf M. F. Berger, Maria Jesus del Cerro, Eric D. Austin, Maurice Beghetti, Dunbar Ivy, Megan Griffiths, Anne Hilgendorff, Steven H. Kawut, Usha S. Krishnan, Mary P. Mullen, Shahin Moledina, Bernard Thébaud, Norman Stockbridge   +14 more
wiley   +1 more source

Stellungnahmerecht der Fachgesellschaften gesetzlich verankert [PDF]

, 2011
Mit der Verabschiedung des Versorgungsstrukturgesetzes sind weitere Stellungnahmerechte der Fachgesellschaften gesetzlich im SGB V verankert - die AWMF organisiert den Kontakt zu G-BA, IQWiG und ...
Müller, W
core   +1 more source

Hazards Constitute Key Quantities for Analyzing, Interpreting and Understanding Time‐to‐Event Data

Biometrical Journal, Volume 67, Issue 3, June 2025.
ABSTRACT Censoring makes time‐to‐event data special and requires customized statistical techniques. Survival and event history analysis therefore builds on hazards as the identifiable quantities in the presence of rather general censoring schemes. The reason is that hazards are conditional quantities, given previous survival, which enables estimation ...
Jan Beyersmann, Claudia Schmoor, Martin Schumacher   +2 more
wiley   +1 more source

Daratumumab (neues Anwendungsgebiet, Multiples Myelom, für Stammzelltransplantation nicht geeignet, Erstlinie) [PDF]

Dieses Verfahren betrifft eine weitere Anwendung von Daratumumab (Darzalex®) in der Erstlinientherapie des Multiplen Myeloms bei Patienten, die nicht für eine autologe Stammzelltransplantation geeignet sind.
Weisel, Katja, Wörmann, Bernhard, Deutsche Studiengruppe Multiples Myelom (DSMM), Goldschmidt, Hartmut, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, German-Speaking Myeloma Multicenter Group (GMMG), Scheid, Christoph, Einsele, Hermann, Knop, Stefan, Röllig, Christoph   +10 more
core   +3 more sources

Machbarkeit und Praktikabilität der anwendungsbegleitenden Datenerhebung (AbD) - Erfahrungen, Analysen und Weiterentwicklungsvorschläge

Monitor Versorgungsforschung
Der Gesetzgeber hat mit dem 2019 eingeführten Instrument der anwendungsbegleitenden Datenerhebung (AbD) die Möglichkeit geschaffen, vergleichende Daten in der laufenden Versorgung zu erheben.
Dr. rer. nat. Matthias Wilken, Fabian Berkemeier MSc   +1 more
doaj   +1 more source